Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $46.00

Maze Therapeutics (NASDAQ:MAZE) had its price target raised by BTIG Research from $37.00 to $46.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the stock.

MAZE has been the topic of several other reports. Wells Fargo & Company assumed coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 target price on the stock. Raymond James Financial initiated coverage on shares of Maze Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price objective for the company. HC Wainwright upped their target price on shares of Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, December 3rd. JPMorgan Chase & Co. increased their target price on shares of Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a report on Monday, September 29th. Finally, Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $44.50.

Maze Therapeutics Trading Up 2.4%

NASDAQ MAZE opened at $40.77 on Friday. The stock has a market capitalization of $1.96 billion and a price-to-earnings ratio of -1.95. The business’s 50 day moving average is $38.71 and its two-hundred day moving average is $27.07. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $43.29.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Insider Activity

In other news, insider Atul Dandekar sold 72,400 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the completion of the transaction, the insider directly owned 10,503 shares of the company’s stock, valued at $426,001.68. This trade represents a 87.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CMO Harold Bernstein sold 25,156 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $40.20, for a total value of $1,011,271.20. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 167,500 shares of company stock worth $6,774,667 over the last ninety days.

Institutional Trading of Maze Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MAZE. Frazier Life Sciences Management L.P. lifted its holdings in Maze Therapeutics by 10.6% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after purchasing an additional 438,274 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Maze Therapeutics by 218.1% in the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after buying an additional 915,342 shares during the last quarter. Woodline Partners LP grew its stake in Maze Therapeutics by 10.0% in the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after acquiring an additional 94,529 shares during the period. Marshall Wace LLP raised its holdings in Maze Therapeutics by 3,868.5% in the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after acquiring an additional 758,104 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC acquired a new position in Maze Therapeutics in the 3rd quarter valued at $14,135,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.